Gerald Hogue
Chief Executive Officer chez Viviphi Ltd.
Profil
Gerald Hogue is the founder of OpTx Corp.
(founded in 1993) and Viviphi Ltd.
(founded in 2015), where he held the title of Chairman, President & Chief Executive Officer.
Currently, he is a Director at POINT Biopharma, Inc. (United States) since 2020.
In the past, he was an Independent Director at POINT Biopharma Global, Inc. from 2021 to 2023.
Postes actifs de Gerald Hogue
Sociétés | Poste | Début |
---|---|---|
Viviphi Ltd.
Viviphi Ltd. Packaged SoftwareTechnology Services Viviphi Ltd., also known as VieCure, is an artificial intelligence platform that has developed a proprietary informatics software platform in conjunction with a clinical inference engine and point-of-care decision support system in oncology. The company is based in Denver, CO. The platform combines the latest in clinical knowledge with patient data to assist clinicians in generating personalized treatment plans and better managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. The company was founded by Fredrick D. Ashbury, Gerald Hogue. Gerald Hogue has been the CEO since incorporation. | Chief Executive Officer | 01/11/2015 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Director/Board Member | 01/12/2020 |
Anciens postes connus de Gerald Hogue
Sociétés | Poste | Fin |
---|---|---|
POIT BIOP | Director/Board Member | 27/12/2023 |
OpTx Corp.
OpTx Corp. Packaged SoftwareTechnology Services Part of Siemens AG, OpTx Corp. is a private company that provides oncology-specific software and services providers. The company is based in Englewood, CO. OpTx was acquired by Varian Medical Systems, Inc., part of Siemens AG from April 15, 2021 on March 29, 2004 for $18 million. The company was founded by Gerald Hogue. | Founder | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
POIT BIOP | Health Technology |
Entreprise privées | 3 |
---|---|
OpTx Corp.
OpTx Corp. Packaged SoftwareTechnology Services Part of Siemens AG, OpTx Corp. is a private company that provides oncology-specific software and services providers. The company is based in Englewood, CO. OpTx was acquired by Varian Medical Systems, Inc., part of Siemens AG from April 15, 2021 on March 29, 2004 for $18 million. The company was founded by Gerald Hogue. | Technology Services |
Viviphi Ltd.
Viviphi Ltd. Packaged SoftwareTechnology Services Viviphi Ltd., also known as VieCure, is an artificial intelligence platform that has developed a proprietary informatics software platform in conjunction with a clinical inference engine and point-of-care decision support system in oncology. The company is based in Denver, CO. The platform combines the latest in clinical knowledge with patient data to assist clinicians in generating personalized treatment plans and better managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. The company was founded by Fredrick D. Ashbury, Gerald Hogue. Gerald Hogue has been the CEO since incorporation. | Technology Services |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Commercial Services |